Inclusion Criteria:

- T1c or T2a carcinoma of the prostate confirmed by biopsy;

- life expectancy of 5(five) years or more;

- prostate biopsy with 10(ten) or more core biopsies;

- Gleason score of 6(six) or less;

- serum Prostate Specific Antigen (PSA) of 10(ten)ng/ml or less;

- prostate volume of less than 40(Forty)cc;

- distance from the Anterior capsule surface to the Posterior capsule surface (AP
Diameter) of 40(Forty)cm or less;

- informed consent for the treatment study through 24 months post-treatment follow-up

Exclusion Criteria:

- men who have had previous definitive treatment for prostate cancer;

- evidence of metastatic disease and/or a previous positive bone-scan, previous
diagnosis or treatment for cancer within the last 5(five) years;

- prior hormonal therapy for prostate cancer (including bilateral orchiectomy);

- inability to tolerate a transrectal ultrasound;

- active urinary tract infection;

- functional bladder problems;

- prior significant rectal surgery;

- intra-prostatic calcifications greater than 1(One)cm in diameter;

- interest in future fertility;

- prostatic surgery/procedure (except biopsy) within 1(One) year;

- large median lobe of the prostate;

- use of medications that can affect PSA within 2(Two) months (e.g. finasteride, saw
palmetto);

- current bladder cancer, urethral stricture, or bladder neck contracture;

- urinary tract and/or rectal fistula;

- rectal fibrosis/stenosis;

- anomaly of the rectal anatomy or mucus membrane;

- prostate seroma/abcess;

- prostatitis;

- compromised renal function or upper urinary tract disease secondary to urinary
obstruction;

- bleeding disorders/coagulopathy based on measures of PT and PTT;

- implant in the prostate or within 1(One)cm of the prostate;

- zip code of the primary residence of the subject is greater than 200(Two hundred)
miles from the clinical site or transportation that would hinder the completion of
the study